Onyx Pharmaceuticals has signed an agreement to acquire Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. Proteolix’s lead compound, carfilzomib, is a proteasome inhibitor currently in multiple clinical trials, including a Phase IIb trial for patients with relapsed and refractory multiple myeloma. “Carfilzomib is a next-genera...